CHRNA7 and schizophrenia: And α7 nicotinic acetylcholine receptors (α7 nAChRs) are currently being investigated as a potential therapeutic target for cognitive disturbances in schizophrenia and Alzheimer disease based on data from small open clinical studies [4].